Clinical Trial

Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)

Name: Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) — clinical trial record (NCT06418087)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DUPLE

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A prospective multicenter, single-arm phase II study enrolling treatment-naïve patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC)

Trial Details

NCT Number	NCT06418087
Lead Sponsor	Gruppo Oncologico Italiano di Ricerca Clinica
Conditions	Pulmonary Large-cell Neuroendocrine Carcinoma
Enrollment	49 participants
Start Date	2022-05-27
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-05-16